Earnings ·
Fresenius Medical Care AG reported second quarter 2026 results with organic revenue growth of 5% to EUR 4,861 million…
FMSFresenius Medical Care AG
Fresenius Medical Care AG reported second quarter 2026 results with organic revenue growth of 5% to EUR 4,861 million and operating income excluding special items up 23% to EUR 569 million. Reported net income decreased by 3% to EUR 218 million due to a EUR 71 million impairment related to the recommended revocation of TAVNEOS marketing authorization. The company advanced its FME Reignite strategy, converting 227 U.S. clinics to the 5008X CAREsystem and exiting approximately 100 clinics as part of the FME25+ program, which generated EUR 67 million in additional sustainable savings. A second share buyback program totaling around EUR 1 billion was initiated on May 28, with 2,454,945 shares repurchased for EUR 94 million by June 30. The company reaffirmed its full-year 2026 outlook, expecting broadly flat revenue growth and operating income within a positive to negative mid-single digit percent range.